Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933502 · ClinicalTrials.gov registry record · Phase 2
Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
A Phase 2 study of Scalp Psoriasis, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT02933502 is a Phase 2 study of Scalp Psoriasis that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 3 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02933502, a Phase 2 study of Scalp Psoriasis, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis
Conditions Studied
Interventions
- DRUG DSXS topical product
Study Locations (1)
New York
- Taro Pharmaceuticals USA Inc. - Hawthorne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-07-11 |
| Est. Completion | 2018-01-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02933502
The ClinicalTrials.gov registry entry for NCT02933502 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Scalp Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which DSXS topical product is the first listed.
NCT02933502 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02933502 about?
NCT02933502 is a clinical study titled "Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product". An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis
What is the current status of trial NCT02933502?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2016-07-11. Estimated completion is 2018-01-02.
What conditions does trial NCT02933502 study?
This clinical trial studies the following conditions: Scalp Psoriasis.
What interventions are being tested in trial NCT02933502?
The interventions under investigation include: DSXS topical product (DRUG).
Who is sponsoring clinical trial NCT02933502?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02933502 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scalp Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.